News | Structural Heart Occluders | February 15, 2017

UAB First in Alabama to Implement New FDA-Approved Amplatzer PFO Occluder

Device reduces risk of recurrent ischemic stroke for 25 to 30 percent of Americans who have a patent foramen ovale

University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation

February 15, 2017 — Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-approved patent foramen ovale occluder in Alabama. 

A PFO is a hole in the heart that does not close the way it should after birth. During fetal development, a small flap-like opening — the foramen ovale — is normally present in the wall between the right and left upper chambers of the heart. It normally closes during infancy. With the new Amplatzer PFO Occluder, ischemic stroke patients will now have access to a closure device shown to reduce risk of recurrent stroke, rather than relying on medical management alone. 

Baker-Dean Endowed Professor in Interventional Cardiology Massoud Leesar, M.D., performed the first procedure Jan. 25, 2017. 

“This new device has the potential to help many patients who suffer from PFO and stroke,” he said. “Our first patient did very well and was discharged the day after the procedure since the echocardiogram showed complete closure of PFO.” 

Approximately 25 to 30 percent of Americans have a PFO, which typically causes no health problems and does not require treatment. The cause of most strokes can be identified, such as poorly controlled high blood pressure, narrowed blood vessels due to cholesterol deposits and scar tissue (atherosclerosis), or a blood clot caused by an abnormal heart rhythm (atrial fibrillation).

“Stroke in patients younger than 60 years old is most likely related to PFO,” Leesar said. “In patients older than 60, other causes such as atherosclerosis and atrial fibrillation will need to be ruled out. These patients are typically referred by neurologists who cannot define other causes for stroke.” 

The Amplatzer PFO Occluder is inserted through a catheter that is placed in a leg vein and advanced to the heart. It is then implanted close to the hole in the heart between the right atrium and the left chamber. The procedure is minimally invasive, and recovery time is minimal.

Nearly 795,000 new or recurrent strokes occur every year in the United States, making it the fifth-leading cause of death and leading cause of serious long-term disability for Americans, according to the American Heart Association. Ischemic strokes account for 87 percent of strokes, and occur when a blood vessel is obstructed, depleting the brain of its blood supply.

The Amplatzer PFO Occluder is developed by St. Jude Medical Inc.

For more information: www.sjm.com 

Related Content

Sponsored Content | Videos | Angiography| June 22, 2017
Shimadzu Medical Systems hghlighted new features of its Trinias Interventional X-ray line at the America College of C
Italian Boy Becomes Youngest Patient Bridged to Transplant With SynCardia Total Artificial Heart

Andrei, 12, is the world’s youngest patient to be bridged to transplant with the SynCardia Total Artificial Heart. He is pictured after his heart transplant with his surgeon, Antonio Amodeo, M.D., at Bambino Gesù Children’s Hospital in Rome, Italy. Photo courtesy of Business Wire.

News | Congenital Heart| June 22, 2017
A 12-year-old boy at Bambino Gesù Children’s Hospital in Rome, Italy, has become the world’s youngest patient to be...
BioTrace Medical's Tempo Lead Shows Stability and Safety in Real-World Performance
News | Leads Implantable Devices| June 20, 2017
BioTrace Medical Inc. announced that the company’s Tempo Temporary Pacing Lead was featured in an oral presentation and...
Stroke2prevent Receives FDA 510(k) Clearance for A-View
Technology | Ultrasound Transesophageal echo (TEE)| June 20, 2017
June 20, 2017 — Dutch medical device company Stroke2prevent BV recently announced it has received U.S.
IABP recall for Maquet, Datascope intra-aortic balloon pump CS100 and CS300

The Datascope CS300 IABP console.

News | Hemodynamic Support Devices| June 20, 2017
June 20, 2017 — The U.S.
Sponsored Content | Videos | Cardiovascular Ultrasound| June 15, 2017
Madhav Swaminathan, M.D., FASC, FAHA, clinical director of cardiothoracic anesthesiology, at Duke Univer
radial access, transradial access trial using anticoagulants
News | Radial Access| June 15, 2017
June 15, 2017 — In patients undergoing t...
Mitral Valve regurgitation showed on an echocardiogram, cardiac ultrasound

Mitral valve regurgitation showed on an echocardiogram. Image from Toshiba.

News | Heart Valve Technology| June 15, 2017
June 15, 2017 — 4C Medical Technologies Inc., a developer of minimally invasive therapies for structural heart diseas
Sponsored Content | Videos | Heart Valve Technology| June 14, 2017
A discussion with Rebecca Hahn, M.D., FASE, director of interventional echocardiography and professor of medicine at
Overlay Init